{"id":1068035,"date":"2020-11-22T13:59:38","date_gmt":"2020-11-22T18:59:38","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/novartis-secures-exclusive-rights-for-potential-acute-respiratory-distress-syndrome-cell-therapy\/"},"modified":"2024-08-18T11:42:09","modified_gmt":"2024-08-18T15:42:09","slug":"novartis-secures-exclusive-rights-for-potential-acute-respiratory-distress-syndrome-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/novartis-secures-exclusive-rights-for-potential-acute-respiratory-distress-syndrome-cell-therapy.php","title":{"rendered":"Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy"},"content":{"rendered":"<p><![CDATA[Basel, November 19, 2020 \u2014 Novartis announced today that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. ARDS is an area of significant unmet need, with an approximate 40% mortality rate with current standard of care, which includes prolonged ICU treatment and mechanical ventilation.1,2 As the potential first ARDS therapy, remestemcel-L will use mesenchymal stromal cells (MSCs), a cell-based platform technology, to treat this deadly condition and improve outcomes. Remestemcel-L is currently being studied in COVID-19-related ARDS in an ongoing 300-patient Phase III study.3 Novartis intends to initiate a Phase III study in non-COVID-19-related ARDS after the anticipated closing of the license agreement and successful completion and outcome of the current study.]]><\/p>\n<p>Read the original here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/11\/19\/2130562\/0\/en\/Novartis-secures-exclusive-rights-for-potential-acute-respiratory-distress-syndrome-cell-therapy.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy\">Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read the original here: Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/novartis-secures-exclusive-rights-for-potential-acute-respiratory-distress-syndrome-cell-therapy.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068035","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068035"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068035"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068035\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}